Masahiko Azuma

Summary

Affiliation: The University of Tokushima
Country: Japan

Publications

  1. ncbi request reprint A report of two bronchioloalveolar carcinoma cases which were rapidly improved by treatment with the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 ("Iressa")
    Seiji Yano
    Department of Internal Medicine, University of Tokushima School of Medicine, Tokushima 770 8503, Japan
    Cancer Sci 94:453-8. 2003
  2. ncbi request reprint Retreatment of lung adenocarcinoma patients with gefitinib who had experienced favorable results from their initial treatment with this selective epidermal growth factor receptor inhibitor: a report of three cases
    Seiji Yano
    Department of Internal Medicine and Molecular Therapeutics, The University of Tokushima Graduate School, 3 18 15 Kuramoto cho, Tokushima, Japan
    Oncol Res 15:107-11. 2005
  3. ncbi request reprint Antitumor vascular strategy for controlling experimental metastatic spread of human small-cell lung cancer cells with ZD6474 in natural killer cell-depleted severe combined immunodeficient mice
    Seiji Yano
    Department of Internal Medicine and Molecular Therapeutics, University of Tokushima School of Medicine, Tokushima, Kuramoto Cho, Tokushima, Japan and AstraZeneca, Macclesfield, United Kingdom
    Clin Cancer Res 11:8789-98. 2005
  4. ncbi request reprint Investigation of the outpatient chemotherapy for lung cancer patients in Tokushima University Hospital
    Hisatsugu Goto
    Department of Respiratory Medicine and Rheumatology, Institute of Health Biosciences, University of Tokushima Graduate School, Tokushima, Japan
    J Med Invest 58:219-26. 2011
  5. doi request reprint Antiallergic and anti-inflammatory effects of a novel I kappaB kinase beta inhibitor, IMD-0354, in a mouse model of allergic inflammation
    Akemi Sugita
    Department of Respiratory Medicine and Rheumatology, Institute of Health Biosciences, University of Tokushima Graduate School, Tokushima, Japan
    Int Arch Allergy Immunol 148:186-98. 2009
  6. doi request reprint Targeted reduction of CCR4⁺ cells is sufficient to suppress allergic airway inflammation
    Akifumi Honjo
    Department of Respiratory Medicine and Rheumatology, Institute of Health Biosciences, The University of Tokushima Graduate School, 3 18 15 Kuramoto cho, Tokushima 770 8503, Japan Electronic address
    Respir Investig 51:241-9. 2013
  7. ncbi request reprint Epidemiological and clinical features of lung cancer patients from 1999 to 2009 in Tokushima Prefecture of Japan
    Takanori Kanematsu
    Department of Medical Oncology, Institute of Health Biosciences, The University of Tokushima Gradate School, Tokushima, Japan
    J Med Invest 57:326-33. 2010
  8. ncbi request reprint Psychiatric symptoms in a patient with Churg-Strauss syndrome
    Toshifumi Tezuka
    Department of Respiratory Medicine and Rheumatology, Institute of Health Biosciences, The University of Tokushima Graduate School, Japan
    Intern Med 51:301-3. 2012
  9. ncbi request reprint Inhaled steroid therapy and hospitalization for bronchial asthma: trend in Tokushima University Hospital
    Hiroaki Yanagawa
    Department of Internal Medicine and Molecular Therapeutics, The University of Tokushima School of Medicine, Tokushima, Japan
    J Med Invest 50:72-7. 2003

Collaborators

Detail Information

Publications9

  1. ncbi request reprint A report of two bronchioloalveolar carcinoma cases which were rapidly improved by treatment with the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 ("Iressa")
    Seiji Yano
    Department of Internal Medicine, University of Tokushima School of Medicine, Tokushima 770 8503, Japan
    Cancer Sci 94:453-8. 2003
    ..These results suggest that this selective EGFR-TKI, ZD1839, may be a powerful agent for treatment of chemotherapy-refractory BAC patients with bronchorrhea...
  2. ncbi request reprint Retreatment of lung adenocarcinoma patients with gefitinib who had experienced favorable results from their initial treatment with this selective epidermal growth factor receptor inhibitor: a report of three cases
    Seiji Yano
    Department of Internal Medicine and Molecular Therapeutics, The University of Tokushima Graduate School, 3 18 15 Kuramoto cho, Tokushima, Japan
    Oncol Res 15:107-11. 2005
    ....
  3. ncbi request reprint Antitumor vascular strategy for controlling experimental metastatic spread of human small-cell lung cancer cells with ZD6474 in natural killer cell-depleted severe combined immunodeficient mice
    Seiji Yano
    Department of Internal Medicine and Molecular Therapeutics, University of Tokushima School of Medicine, Tokushima, Kuramoto Cho, Tokushima, Japan and AstraZeneca, Macclesfield, United Kingdom
    Clin Cancer Res 11:8789-98. 2005
    ..Small-cell lung cancer is often characterized by rapid growth and metastatic spread. Because tumor growth and metastasis are angiogenesis dependent, there is great interest in therapeutic strategies that aim to inhibit tumor angiogenesis...
  4. ncbi request reprint Investigation of the outpatient chemotherapy for lung cancer patients in Tokushima University Hospital
    Hisatsugu Goto
    Department of Respiratory Medicine and Rheumatology, Institute of Health Biosciences, University of Tokushima Graduate School, Tokushima, Japan
    J Med Invest 58:219-26. 2011
    ..1 months and 4.8 months in SCLC and NSCLC, respectively. These findings indicate that even in the setting of clinical practice, the efficacy and safety of chemotherapy is strictly insured by the appropriate therapeutic management...
  5. doi request reprint Antiallergic and anti-inflammatory effects of a novel I kappaB kinase beta inhibitor, IMD-0354, in a mouse model of allergic inflammation
    Akemi Sugita
    Department of Respiratory Medicine and Rheumatology, Institute of Health Biosciences, University of Tokushima Graduate School, Tokushima, Japan
    Int Arch Allergy Immunol 148:186-98. 2009
    ..This study aimed to elucidate the antiallergic effects of a newly synthesized IKK beta inhibitor, IMD-0354, in a mouse model of allergic inflammation...
  6. doi request reprint Targeted reduction of CCR4⁺ cells is sufficient to suppress allergic airway inflammation
    Akifumi Honjo
    Department of Respiratory Medicine and Rheumatology, Institute of Health Biosciences, The University of Tokushima Graduate School, 3 18 15 Kuramoto cho, Tokushima 770 8503, Japan Electronic address
    Respir Investig 51:241-9. 2013
    ..To test our hypothesis, we examined whether TARC-PE38 could suppress allergic airway inflammation in a mouse model of house dust mite (HDM)-induced allergic airway inflammation...
  7. ncbi request reprint Epidemiological and clinical features of lung cancer patients from 1999 to 2009 in Tokushima Prefecture of Japan
    Takanori Kanematsu
    Department of Medical Oncology, Institute of Health Biosciences, The University of Tokushima Gradate School, Tokushima, Japan
    J Med Invest 57:326-33. 2010
    ..3 months and 18.0 months, respectively, which were comparable with those of total population. These results indicated the benefit of chemotherapy in elderly patients with advanced lung cancer by proper selection...
  8. ncbi request reprint Psychiatric symptoms in a patient with Churg-Strauss syndrome
    Toshifumi Tezuka
    Department of Respiratory Medicine and Rheumatology, Institute of Health Biosciences, The University of Tokushima Graduate School, Japan
    Intern Med 51:301-3. 2012
    ..Though multiple cerebral infarctions are irreversible, this patient's psychiatric symptoms improved with steroid treatment. Psychiatric symptoms associated with CSS are very rare...
  9. ncbi request reprint Inhaled steroid therapy and hospitalization for bronchial asthma: trend in Tokushima University Hospital
    Hiroaki Yanagawa
    Department of Internal Medicine and Molecular Therapeutics, The University of Tokushima School of Medicine, Tokushima, Japan
    J Med Invest 50:72-7. 2003
    ....